Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07332000 · ClinicalTrials.gov registry record · Phase 2
A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec
A Phase 2 study of Prostate Cancer (Adenocarcinoma) and Prostate Cancer Patients Treated by Radiotherapy, sponsored by Candel Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
- 7
- Study locations
NCT07332000 is a Phase 2 study of Prostate Cancer (Adenocarcinoma) and Prostate Cancer Patients Treated by Radiotherapy that is actively recruiting participants, run by Candel Therapeutics. The registered enrollment target is 45 participants, below the 127-participant average among 13 other Prostate Cancer (Adenocarcinoma) trials with a reported enrollment target (65% lower). The trial reports 7 study locations across 6 states.
The verdict
NCT07332000, a Phase 2 study of Prostate Cancer (Adenocarcinoma) and Prostate Cancer Patients Treated by Radiotherapy, is actively recruiting participants, sponsored by Candel Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
- 7
- Study locations
Study Summary
Phase 2a, open-label, multi-center study evaluating biomarkers and biodistribution of aglatimagene besadenovec plus valacyclovir in men with localized, intermediate-risk prostate cancer who are planning to receive external beam radiation therapy (EBRT).
Conditions Studied
Interventions
- BIOLOGICAL aglatimagene besadenovec + valacyclovir
- RADIATION External Beam Radiation Therapy (EBRT)
Study Locations (7)
Colorado
- Colorado Clinical Research - Lakewood
- Urology Associates - Littleton
Arizona
- Academic Urology and Urogynecology of Arizona - Peoria
Maryland
- Chesapeake Urology Research Associates - Towson
Nevada
- Sheldon Freedman, MD Ltd. - Las Vegas
New Jersey
- Summit Health - Saddle Brook
South Carolina
- START Carolinas - Myrtle Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2025-10-30 |
| Est. Completion | 2026-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07332000
The ClinicalTrials.gov registry entry for NCT07332000 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 127-participant average among 13 other Prostate Cancer (Adenocarcinoma) trials with a reported enrollment target (65% lower). The listed sponsor is Candel Therapeutics, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Prostate Cancer (Adenocarcinoma) appearing as the primary indexed condition, and to 2 interventions - of which aglatimagene besadenovec + valacyclovir is the first listed.
NCT07332000 reports 7 study locations spanning 6 distinct geographic areas - top geographies include Colorado, Arizona, Maryland.
Frequently Asked Questions
What is clinical trial NCT07332000 about?
NCT07332000 is a clinical study titled "A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec". Phase 2a, open-label, multi-center study evaluating biomarkers and biodistribution of aglatimagene besadenovec plus valacyclovir in men with localized, intermediate-risk prostate cancer who are planning to receive external beam radiation therapy (EBRT).
What is the current status of trial NCT07332000?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2025-10-30. Estimated completion is 2026-08.
What conditions does trial NCT07332000 study?
This clinical trial studies the following conditions: Prostate Cancer (Adenocarcinoma), Prostate Cancer Patients Treated by Radiotherapy.
What interventions are being tested in trial NCT07332000?
The interventions under investigation include: aglatimagene besadenovec + valacyclovir (BIOLOGICAL), External Beam Radiation Therapy (EBRT) (RADIATION).
Who is sponsoring clinical trial NCT07332000?
This trial is sponsored by Candel Therapeutics, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07332000 being conducted?
This trial has 7 study locations across Arizona, Colorado, Maryland, Nevada, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer (Adenocarcinoma)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer
RECRUITING · Phase 2
-
Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer
RECRUITING · Phase 2
-
Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy
RECRUITING · Phase 2
-
A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate
RECRUITING · Phase 2
-
Prostate Oncologic Therapy While Ensuring Neurovascular Conservation (POTEN-C)
ACTIVE NOT RECRUITING · Phase 2
-
Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer
RECRUITING · Phase 1
Explore more on PlainTrial
Prostate Cancer (Adenocarcinoma)
All registered trials for this condition
Prostate Cancer Patients Treated by Radiotherapy
All registered trials for this condition
Arizona
All trials with a study site in Arizona
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.